Fig. 8

(a) A diagrammatic illustration of the preparation, the intestinal lymphatic transit, and the immunomodulatory effect that CHA-SME has on immune cells. (b) Imaging of the distribution of DiR-labeled CHA-SME throughout the intestinal tract ex vivo at numerous predetermined time points after oral administration of the drug. The mice who were given cycloheximide as a pretreatment before having CHA-SME that was labeled with DiR orally administered to them are referred to as “SME + Cyc” animals. the same as what was said in the previous section. (c) Imaging of the distribution of DiR-labeled CHA-SME in MLNs ex vivo following oral administration of the drug at a number of predetermined time periods after imaging the distribution of the compound in MLNs in vivo. (d) The quantity of DIR and DiR-labeled CHA-SME that built up in MLNs at specific points in time during the experiment. (n = 3–4) The mean and the standard error of the mean are both indicated by each value. (e) The amount of high-quality DiR and DiR-labeled CHA-SME that had accumulated in MLNs after 0.5 h was of a very high standard. Each figure represents the mean standard error of the mean for a sample size of between three and four. **P < 0.01, ***P < 0.001. The abbreviation for mesenteric lymph nodes is MLNs. Chlorogenic acid-encapsulated SMEDDS is what the acronym CHA-SME refers to. The chemical name for this compound is “1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide.“ [121]